Drug-Resistant TB Dashboard

The Problem

Globally in 2017, an estimated 3.6 percent of new and 17 percent of previously treated TB cases had rifampicin-resistance (RR-TB) or multi-drug (combined rifampicin and isoniazid) resistant tuberculosis (MDR-TB) [WHO]. These cases require more complex treatment. To start, drug-susceptibility testing (DST) is recommended for all persons with signs and symptoms of TB. How is your country addressing drug-resistant TB?

Looking at Data

Take a look at the data in your country by following a series of questions. Share your insights at hub@tbdiah.org.

What number and percent of people with bacteriologically confirmed pulmonary TB are being tested for drug susceptibility to rifampicin in my country?

Since microbiological detection of TB is also linked to drug resistance testing to ensure that TB patients are put on the most effective treatment regimen, are people presumed to have pulmonary TB getting diagnosed bacteriologically in the first place in my country?

What number of people with bacteriologically confirmed pulmonary TB tested rifampicin-resistant and multi-drug-resistant in my country?

Among DR-TB cases, i.e., people who have rifampicin-resistant (RR)-TB and are resistant to any fluoroquinolone, what is the comparative burden of pre-extensively drug-resistant (pre-XDR) and extensively drug resistant (XDR)-TB cases?

Once tested and notified, patients with DR-TB are enrolled in treatment. Are all the people who have been diagnosed with DR-TB getting enrolled for treatment in my country?

What is the outcome of the treatment of these people with DR-TB? That what proportion of these people with DR-TB get successfully treated, what proportion died or were lost to follow-up or their treatment failed, or were not evaluated at all??

How does the DR-TB treatment cascade look like over the years? How many people with DR-TB are lost at every stage of the treatment cascade?

What proportion of TB patients tested for drug susceptibility are resistant to only rifampicin or only INH? These data provide an important insight into the trends of drug resistance.

About the Data


For questions and comments pertaining to the hub and source data, please email: hub@tbdiah.org.